Dr. Agarwal's Eye Hospital Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors, meeting on May 20, 2026, approved the results and recommended a final dividend for the financial year.

Financial Performance for FY26

For the full year ended March 31, 2026, the company reported a 28% increase in net profit to INR 70.10 Cr, compared to INR 54.65 Cr in the previous year. Revenue from operations for the year rose to INR 470.87 Cr from INR 397.15 Cr in FY25. Earnings Per Share (EPS) for the year stood at INR 147.02, up from INR 116.28 in the prior year.

Q4 Performance

In the quarter ended March 31, 2026, revenue from operations grew to INR 120.01 Cr from INR 99.83 Cr in the corresponding quarter of the previous year. Net profit for the quarter increased to INR 16.24 Cr from INR 15.99 Cr. EBITDA for the quarter stood at INR 35.30 Cr.

Dividend Declaration

The Board has recommended a final dividend of INR 4 per equity share of INR 10 each fully paid-up for the financial year ended March 31, 2026. This is in addition to the interim dividend of INR 3 per share declared earlier, bringing the total dividend for the year to INR 7 per share. The dividend is subject to approval by shareholders at the ensuing Annual General Meeting.

The Hon'ble National Company Law Tribunal (NCLT), Chennai Bench, has allowed the joint First Motion Application filed by Dr. Agarwal's Health Care Limited (AHCL) and Dr. Agarwal's Eye Hospital Limited (AEHL), marking a significant procedural milestone in the proposed Scheme of amalgamation between the two companies. Both companies have independently disclosed the development to the stock exchange under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The hearing was held on May 05, 2026, and the formal written Order was uploaded on the NCLT website on May 11, 2026.

NCLT Order: Key Details

The Order directs AHCL and AEHL to convene their respective meetings of shareholders and creditors for the purpose of considering and, if thought fit, approving — with or without modification(s) — the amalgamation embodied in the Scheme. The following key details pertain to the meetings as directed by the NCLT:

Background and Prior Disclosures

The disclosures reference prior communications made to the stock exchange, including letters dated February 17, 2026, and August 27, 2025, indicating that the amalgamation process has been underway for a considerable period. The Scheme involves the amalgamation of AHCL and AEHL along with their respective shareholders and creditors, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, read with the rules and/or regulations framed thereunder.

Next Steps and Pending Approvals

The certified copy of the NCLT Order is currently awaited and will be made available on the websites of both AHCL and AEHL promptly upon its receipt. Both companies have stated that other relevant details pertaining to the aforementioned meetings, along with copies of the notices, shall be submitted to the stock exchange in due course. Importantly, the Scheme remains subject to the receipt of all necessary statutory and regulatory approvals as may be required under applicable laws.

The disclosure on behalf of Dr. Agarwal's Health Care Limited was signed by Thanikainathan Arumugam, Company Secretary and Compliance Officer, and was digitally authenticated on May 11, 2026. The corresponding disclosure on behalf of Dr. Agarwal's Eye Hospital Limited was signed by Meenakshi Jayaraman, Company Secretary and Compliance Officer, also on May 11, 2026.